Mostrar el registro sencillo del ítem

dc.contributor.authorMariño Callejo, Ana Isabel 
dc.contributor.authorValcarce Pardeiro, Nieves 
dc.contributor.authorAlende Castro, Vanesa 
dc.contributor.authorBrea Aparicio, Ruth
dc.contributor.authorBarbeito Castiñeiras, Gema 
dc.contributor.authorDomínguez Santalla, María Jesús 
dc.date.accessioned2021-11-18T09:06:00Z
dc.date.available2021-11-18T09:06:00Z
dc.date.issued2020
dc.identifier.issn1198-743X
dc.identifier.otherhttps://pubmed.ncbi.nlm.nih.gov/32758659/es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15663
dc.description.abstractObjectives: To analyse the characteristics and predictors of death in hospitalized patients with coronavirus disease 2019 (COVID-19) in Spain. Methods: A retrospective observational study was performed of the first consecutive patients hospitalized with COVID-19 confirmed by real-time PCR assay in 127 Spanish centres until 17 March 2020. The follow-up censoring date was 17 April 2020. We collected demographic, clinical, laboratory, treatment and complications data. The primary endpoint was all-cause mortality. Univariable and multivariable Cox regression analyses were performed to identify factors associated with death. Results: Of the 4035 patients, male subjects accounted for 2433 (61.0%) of 3987, the median age was 70 years and 2539 (73.8%) of 3439 had one or more comorbidity. The most common symptoms were a history of fever, cough, malaise and dyspnoea. During hospitalization, 1255 (31.5%) of 3979 patients developed acute respiratory distress syndrome, 736 (18.5%) of 3988 were admitted to intensive care units and 619 (15.5%) of 3992 underwent mechanical ventilation. Virus- or host-targeted medications included lopinavir/ritonavir (2820/4005, 70.4%), hydroxychloroquine (2618/3995, 65.5%), interferon beta (1153/3950, 29.2%), corticosteroids (1109/3965, 28.0%) and tocilizumab (373/3951, 9.4%). Overall, 1131 (28%) of 4035 patients died. Mortality increased with age (85.6% occurring in older than 65 years). Seventeen factors were independently associated with an increased hazard of death, the strongest among them including advanced age, liver cirrhosis, low age-adjusted oxygen saturation, higher concentrations of C-reactive protein and lower estimated glomerular filtration rate. Conclusions: Our findings provide comprehensive information about characteristics and complications of severe COVID-19, and may help clinicians identify patients at a higher risk of death.es
dc.description.sponsorshipFundación SEIMC/GeSIDAes
dc.description.sponsorshipPlan Nacional de I+D+i 2013-2016es
dc.description.sponsorshipInstituto de Salud Carlos III (ISCIII)es
dc.description.sponsorshipMinisterio de Ciencia, Innovación y Universidadeses
dc.description.sponsorshipEuropean Regional Develpment Fund (ERDF)es
dc.description.sponsorshipOperative Program Intelligent Growth 2014-2020es
dc.description.sponsorshipSpanish AIDS Research Network (RIS)es
dc.description.sponsorshipSpanish Network for Research in Infectious Diseaseses
dc.language.isoenges
dc.subject.meshCoronavirus*
dc.subject.meshDigitalis*
dc.subject.meshIntensive Care*
dc.subject.meshSevere Acute Respiratory Syndrome*
dc.subject.meshCopyright*
dc.subject.meshObesity*
dc.subject.meshWork*
dc.subject.meshAged*
dc.titleCharacteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spaines
dc.typeArtigoes
dc.bbddEmbase*
dc.bbddWOK*
dc.contributor.authorcorpCOVID-19@Spain Study Groupes
dc.issue.number11es
dc.journal.titleClinical Microbiology and Infectiones
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ferrol – Complexo Hospitalario Universitario de Ferrol::Farmaciaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ferrol – Complexo Hospitalario Universitario de Ferrol::Medicina Internaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Pontevedra e O Salnés - Hospital do Salnéses
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostelaes
dc.page.initial1525es
dc.page.final1536es
dc.relation.projectIDinfo:eurepo/grantAgreement/Spanish AIDS Research Network(RIS)///RD16%2F0025%2F0017///es
dc.relation.projectIDinfo:eurepo/grantAgreement/Spanish AIDS Research Network(RIS)///RD16%2F0025%2F0018///es
dc.relation.projectIDinfo:eurepo/grantAgreement/Spanish AIDS Research Network(RIS)///RD16ciii%2F0005%2F006///es
dc.relation.projectIDinfo:eurepo/grantAgreement/Spanish Network for Research in Infectious Diseases(REIPI)///RD16%2F0016%2F001///es
dc.relation.projectIDinfo:eurepo/grantAgreement/Spanish Network for Research in Infectious Diseases(REIPI)///RD16%2F0005///es
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S1198743X20304316?via%3Dihubes
dc.rights.accessRightsopenAccesses
dc.subject.decstrabajo*
dc.subject.decsanciano*
dc.subject.decscuidados intensivos*
dc.subject.decssíndrome respiratorio agudo grave*
dc.subject.decsobesidad*
dc.subject.decsDigitalis*
dc.subject.decsderechos de autor*
dc.subject.decscoronavirus*
dc.subject.keywordCHUFes
dc.subject.keywordCHUSes
dc.subject.keywordCHUPes
dc.subject.keywordCOVID-19es
dc.typefidesArtigo Científico (inclue Orixinal, Orixinal breve, Revisión Sistemática e Meta-análisis)es
dc.typesophosArtículo Originales
dc.volume.number26es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem